Abstract Anesthetic isoflurane has been reported to induce caspase-3 activation. The underlying mechanism(s) and targeted intervention(s), however, remain largely to be determined. Vitamin C (VitC) inhibits oxidative stress and apoptosis. We therefore employed VitC to further determine the upstream mechanisms and the down-stream consequences of the isoflurane-induced caspase-3 activation. H4 human neuroglioma cells overexpressed human amyloid precursor protein (H4-APP cells) and rat neuroblastoma cells were treated either with (1) 2 % isoflurane or (2) with the control condition, plus saline or 400 μM VitC for 3 or 6 h. Western blot analysis and fluorescence assay were utilized at the end of the experiments to determine caspase-3 activation, levels of reactive oxygen species and ATP, and mitochondrial function. The interaction of isoflurane (1.4 % for 2 h) and VitC (100 mg/kg) on cognitive function in mice was also assessed in the fear conditioning system. Here, we show for the first time that the VitC treatment attenuated the isoflurane-induced caspase-3 activation. Moreover, VitC mitigated the isofluraneinduced increases in the levels of reactive oxygen species, opening of mitochondrial permeability transition pore, reduction in mitochondrial membrane potential, and the reduction in ATP levels in the cells. Finally, VitC ameliorated the isoflurane-induced cognitive impairment in the mice. Pending confirmation from future studies, these results suggested that VitC attenuated the isoflurane-induced caspase-3 activation and cognitive impairment by inhibiting the isoflurane-induced oxidative stress, mitochondrial dysfunction, and reduction in ATP levels. These findings would promote further research into the underlying mechanisms and targeted interventions of anesthesia neurotoxicity.
Introduction
Alzheimer's disease (AD) is one of the greatest public health problems in the USA and in the world, and its impact will only increase with demographic changes anticipated in the coming decades. Anesthesia may potentially facilitate the development of AD dementia [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Specifically, in a retrospective study, Chen et al. investigated one million patients and found that previous exposure to surgery and anesthesia could contribute to the development of AD [11] . In a different study, Liu et al. reported that surgery under sevoflurane anesthesia could facilitate the progression of cognitive function decline in patients who already had mild cognitive impairment [13] . In another retrospective study, Chen et al. included 24,901 patients in the anesthesia/surgery group and 110,972 participants in the control group and found that the hazard ratio of anesthesia and surgery as risk factors for dementia was 1.99 [12] . However, other findings have also suggested the opposite that there is no association between anesthesia and dementia [14] [15] [16] [17] . Further clinical investigation is required in order to determine whether anesthesia and surgery can contribute to AD neuropathogenesis and progression.
Despite this need for greater clinical investigations, it is a fact that conducting more clinical studies, and analyzing the results of these studies, would necessitate a longer time frame. Therefore, it is equally important to investigate the potential neurotoxicity of anesthesia in animals. Understanding anesthesia's potential role in promoting AD neuropathogenesis in animals, as well as learning the underlying mechanisms and targeted interventions of anesthesia in vitro and in animals, may lead to findings with translational potential for future human studies.
The commonly used inhalation anesthetic, isoflurane, has been shown to induce caspase-3 activation, oligomerization and accumulation of β-amyloid protein (Aβ), and learning and memory impairment [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . The up-stream mechanisms, down-stream consequences, and targeted interventions of this isoflurane-induced caspase activation, however, remain largely to be determined.
We have previously shown that isoflurane can increase the levels of reactive oxygen species (ROS), induce mitochondrial dysfunction [e.g., opening of mitochondrial permeability transition pores (mPTPs) and reduction in mitochondrial membrane potential (MMP)], and decrease adenosine triphosphate (ATP) levels, which may subsequently cause caspase-3 activation, leading to learning and memory impairment [27, 28] . Vitamin C (VitC) has been shown to inhibit oxidative stress and apoptosis [29] [30] [31] [32] [33] [34] [35] [36] . We therefore assessed in our studies whether or not VitC could attenuate the isoflurane-induced caspase-3 activation through a ROS-, mitochondria-, and ATP-associated mechanism in cultured cells and whether VitC could also ameliorate the associated isoflurane-induced cognitive impairment seen in rodents. The primary hypothesis in the current studies was that VitC would attenuate the isoflurane-induced caspase-3 activation. The secondary hypothesis was that VitC would attenuate the isoflurane-induced ROS accumulation, mitochondrial dysfunction, and ATP reduction (potential up-stream mechanisms of the isofluraneinduced caspase-3 activation), as well as would ameliorate the isoflurane-induced cognitive impairment (potential downstream consequence of the isoflurane-induced caspase-3 activation). The objectives of the current studies were to seek targeted intervention into the neurotoxicity of isoflurane and its related neurobehavioral deficits, as well as to further demonstrate the up-stream mechanisms and the down-stream consequences of isoflurane-induced caspase-3 activation. We performed the studies both in cultured cells and in mice.
Methods

Cell Line
We employed H4 human neuroglioma cells, stably transfected to express full-length human amyloid precursor protein (H4-APP cells), in the studies to determine whether VitC could attenuate isoflurane-induced cellular neurotoxicity. We chose this particular cell line (H4-APP cells) because we have already shown the isoflurane-induced neurotoxicity in the H4-APP cells [27, 28, 22, 20] . The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (high glucose) containing 9 % heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM Lglutamine and were supplemented with 220 μg/ml G418. H4-APP cells may not be suitable for flow cytometry studies owing to their potential auto-fluorescence [27] . Therefore, we also used rat neuroblastoma cells ((B104 cells), generous gifts from Dr. Dora Kovacs and Dr. Doo Kim of the Massachusetts General Hospital and Harvard Medical School)) in the mPTP experiments, as demonstrated in our previous studies [27] . The B104 cells were cultured in DMEM containing 9 % heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine.
Treatments for Cells Isoflurane was delivered from an anesthesia machine to a sealed plastic box in a 37°C incubator containing 6-well plates or 96-well plates; the six-well plates were seeded with one million cells in 1.5-ml cell culture media per well, and the 96-well plates were seeded with 50,000 cells in 200-μl cell culture media per well, as described in our previous studies [27] . A Datex infrared gas analyzer (Puritan-Bennett, Tewksbury, MA, USA) was used to continuously monitor the delivered concentrations of carbon dioxide, oxygen, and isoflurane. The cells were treated with 2 % isoflurane, plus 21 % O 2 and 5 % CO 2 , for duration of 6 h for the studies of caspase-3 activation and ROS and for duration of 3 h for the studies of mPTP opening, MMP, and ATP, as described by Xie et al. [22] and Zhang et al. [37] . These treatments of isoflurane were chosen according to findings from our previous studies, which revealed that treatment with 2 % isoflurane for 6 h had induced caspase-3 activation and ROS accumulation, and treatment with 2 % isoflurane for 3 h had induced mPTP opening, MMP reduction, and decrease in ATP levels [22, 37] . VitC (400 μM) [38] was given to the cells 30 min before the isoflurane treatments.
Cell Lysis and Protein Quantification
The pellets of the harvested cells were detergent-extracted on ice using an immunoprecipitation buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5 % Nonidet P-40), plus protease inhibitors (1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin A), as described in our previous studies [39] . The lysates were collected, centrifuged at 13,000 rpm for 15 min, and quantified for total protein amount by a bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA).
Western Blot Analyses The harvested cells were subjected to Western blot analyses, as described in our previous studies [28, 27, 39] . Specifically, a caspase-3 antibody (1:1,000 dilution; Cell Signaling Technology, Danvers, MA, USA) was used to recognize full-length caspase-3 (35-40 kDa) and caspase-3 fragments (17-20 kDa) resulting from cleavage at aspartate position 175. Antibody anti-β-actin (1:10,000, Sigma, St. Louis, MO, USA) was used to detect β-actin (42 kDa).
Each band in the Western blot represented an independent experiment. The results were averaged from six independent experiments. The intensity of signals was analyzed using the National Institutes of Health image program. We quantified the Western blots in two steps. First, we used β-actin levels to normalize protein levels (e.g., determining the ratio of caspase-3 fragment to β-actin amount) and to control for loading differences in the total protein amount. Second, we presented protein level changes in cells exposed to anesthesia as a percentage of those in the control group. One hundred percent of the protein level changes refer to the control levels, for the purpose of comparison to the experimental conditions. ROS Measurement An OxiSelect Intracellular ROS Assay Kit and an OxiSelect In Vitro ROS/RNS Assay Kit (Cell Biolabs, San Diego, CA, USA) were used to measure the amount of ROS in cells, according to the protocol provided by the company and our previous studies [28, 27, 39] . In short, cultured H4-APP cells were placed in a clear 96-well cell culture plate in the incubator overnight. We then added the 2′,7′-dichlorfluorescein-diacetate (DCFH-DA) solution to the cells. The DCFH-DA-loaded H4-APP cells were subsequently exposed to 2 % isoflurane for 6 h. These treated cells were first lysed by adding 100 μl of cell lysis buffer and then mixed thoroughly and incubated for 5 min at room temperature. The mixture (150 μl) was transferred to each well of a 96-well plate to be used for fluorescence measurement. Finally, the fluorescence was read with a fluorometric plate reader at 480/ 530 nm.
Flow Cytometric Analysis of mPTP Opening B104 cells were treated with 2 % isoflurane for 3 h. The opening of mPTP was determined by flow cytometry, using the MitoProbe™ Transition Pore Assay Kit (Invitrogen, Carlsbad, CA, USA), as described in our previous studies [27] . Specifically, in normal conditions, the non-fluorescent acetoxymethyl ester (AM) of calcein dye (calcein AM) and cobalt can enter the cells. The AM groups are cleaved from calcein via non-specific esterase, and calcein can then show fluorescent signals in both the cytosol and mitochondria. Cobalt can quench the cytosolic calcein signal. However, cobalt cannot enter healthy mitochondria freely and therefore cannot quench the mitochondrial calcein signal. When the opening of mPTP occurs, cobalt enters through the pore and subsequently quenches the mitochondrial calcein signal. Flow cytometry was used to detect the amount of cells that exhibit quenched calcein signals inside the mitochondria. The location of the curves indicates the amount of cells with quenched calcein signals, which suggests the opening of mPTP. Dead cells and debris were excluded from analysis by gates set on forward and side angle light scatter. We used inomycin as a positive control in the mPTP assay, as described in our previous studies [27] .
Determination of MMP MMP level was calculated by tetraethylbenzimidazolylcarbocyanine iodide (JC-1) fluorescence ratio detection. Specifically, H4-APP cells were placed into 96-well plates with densities of 50,000 per well into the incubator overnight. The cells were washed with 100 μl DPBS twice before isoflurane treatment. At the end of the treatments, cells were incubated with JC-1 reagents at 37°C for 15 min and washed twice with Hanks balanced salt solution (HBSS). Finally, fluorescence was read with a fluorometric plate reader for red fluorescence (exCitation 590 nm, emission 610 nm) and with a fluorescence plate reader for green fluorescence (excitation 490 nm, emission 520 nm). The level of MMP was calculated by the ratio of red fluorescence to green fluorescence. We also used tetramethylrhodamine ethyl ester and perchlorate (TMRE) (Sigma, St. Louis, MO, USA) to measure levels of MMP. TMRE is a cationic dye that is rapidly and reversibly accumulated by healthy mitochondria. A decrease in levels of TMRE immunostaining indicates reduction in MMP levels. The TMRE studies were performed as described by Zhang et al. [27] . Briefly, at the end of the treatment, the cells were treated with 100 nM TMRE for 30 min at 37°C. The cells were washed with HBSS twice and then analyzed under a ×40 objective lens fluorescence microscope.
ATP Measurement
We employed the ATP Determination Kit (Invitrogen) in the experiments to detect ATP levels, as described in our previous studies [27, 28] . In short, H4-APP cells were placed in six-well plates in the incubator overnight. The cells were then exposed to isoflurane treatment for 3 h. At the end of the treatment, the amount of fluorescence was measured, and the levels of ATP in the experimental samples were calculated from the standard curve made from samples containing known amounts of ATP.
Mice The animal protocol was approved by the Standing Committee on Animals at Massachusetts General Hospital, Boston, Massachusetts. Wild-type C57BL/6J mice (8 months old, The Jackson Laboratory, Bar Harbor, ME, USA) were randomly assigned to the anesthesia group or the control group and then were further divided into the saline group or the VitC treatment group. The mice were housed in a controlled environment (20-22°C; 12 h light/dark on a reversed light cycle) for 1 week prior to the studies. The maintenance and handling of the mice were consistent with the guidelines set forth by the National Institutes of Health, and all efforts were made to minimize the number of animals utilized in the studies. Power analyses used to establish experimental group sizes are described below in the statistics section.
Mice Anesthesia The mice (ten per group) were randomized by weight and gender either into experimental groups that received 1.4 % isoflurane plus 100 % oxygen for 2 h or into control groups that received 100 % oxygen for 2 h, at identical flow rates and in identical anesthetizing chambers. The size of the induction chamber in the current study was 20×20×7 cm. The induction flow rate was 2 liter per minute for the first 3 min (for the induction) and then 0.2 liter per minute afterward (for maintenance). The anesthetic and oxygen concentrations were measured continuously by a gas analyzer (Ohmeda, GE Healthcare, Tewksbury, MA, USA). The temperature of the anesthetizing chamber was controlled by the DC Temperature Control System (FHC, Bowdoinham, ME, USA), which is a feedback-based system for monitoring and controlling temperature, to maintain the rectal temperature of the mice at 37±0.5°C. In the interaction studies, dehydroascorbic acid, the oxidized form of VitC, which can enter into the brain through the blood-brain barrier (100 mg/kg), or saline was administered to the mice via tail vein injection 30 min before the isoflurane anesthesia. The dosage of VitC was chosen, with modification, according to previous studies [40, 41] .
Fear Conditioning System (FCS) The FCS (Stoelting Co., Wood Dale, IL, USA)was performed just as described in previous studies [42, 27, 43, 44] , with modification. Briefly, the pairing of the FCS was performed 2 h after the isoflurane anesthesia. The first context and tone tests were performed 24 h after the end of the pairing. The second and third context and tone tests were performed 48 h and 7 days after the anesthesia, respectively. The pairing in the FCS was performed 2 h after the isoflurane anesthesia. Each mouse was allowed to explore the FCS chamber for 180 s before presentation of a 2-Hz pulsating tone (80 dB, 3,600 Hz) that persisted for 60 s. The tone was followed immediately by a mild foot shock (0.8 mA for 0.5 s). The first context test was performed 24 h after the end of the pairing. Each mouse was allowed to stay in the chamber for a total of 390 s. Learning and memory function in the context test was assessed by measuring the amount of time that the mouse demonstrated "freezing behavior," which is defined as a completely immobile posture, except for respiratory efforts, during the second period of 180 s. The first tone test was also performed 24 h after the end of the pairing. Each mouse was allowed to stay in the chamber for a total of 390 s. The same tone was presented for the second 180 s without the foot shock. Learning and memory function in the tone test was also assessed by measuring the amount of time that the mouse demonstrated "freezing behavior," which is defined as a completely immobile posture, albeit for respiratory efforts, during the second period of 180 s. The second and third context and tone tests were performed 48 h and 7 days after the anesthesia, respectively. The "freezing behavior" was then analyzed by Any-Maze (freezing on threshold 10; freezing off threshold 20; minimum freezing duration 1 s) (Stoelting).
Statistical Analyses Data were expressed as means±standard deviation (SD). The number of samples was ten per group for the mice experiments and six per group for the in vitro studies. The power calculation was performed using information collected from a preliminary study that was conducted under the same conditions. Based on the preliminary data, assuming a two-sided Student t test, samples of six and ten for each control and treatment group for the in vitro studies and the mice studies, respectively, would lead to 90 % power and 95 % significance. A two-way ANOVA was used to assess the interaction of VitC with isoflurane and to test the hypothesis that VitC would mitigate the effects of isoflurane on caspase-3 activation, ROS, mPTP, MMP, ATP, and freezing time. Post hoc analyses were conducted if the main effects were found to be statistically significant. The cutoff P value was Bonferroni-adjusted to correct for subset analysis, e.g., comparing the level of isoflurane caspase-3 activation between VitC and saline treatments. The nature of the hypothesis testing was two tailed. P values less than 0.05 were considered statistically significant. SAS software (Cary, NC, USA) and Prism 6 software (La Jolla, CA, USA) were used to analyze the data.
Results
VitC Attenuates Isoflurane-Induced Caspase-3 Activation
Anesthetic isoflurane has been suggested to induce both caspase-3 activation and cognitive impairment by causing mitochondrial dysfunction and oxidative stress [28, 27] . VitC, on the other hand, has been reported to inhibit oxidative stress. Thus, we set out to determine whether VitC could attenuate isoflurane-induced neurotoxicity and neurobehavioral deficits in cultured cells (e.g., H4-APP cells) and in mice. Immunoblotting of caspase-3 showed that treatment with 2 % isoflurane plus saline for 6 h (lane 2) induced a visible increase in the level of the Western blot band representing the caspase-3 fragment compared to the control condition plus saline for 6 h (lane 1) (Fig. 1a) . The treatment with VitC alone (lane 3) did not significantly alter the level of caspase-3 fragment compared to the control condition (lane 1). However, there was a lesser visible band representing the caspase-3 fragment following the treatment with isoflurane plus VitC (lane 4) compared to the treatment with isoflurane plus saline (lane 2) (Fig. 1a) . There were no significant differences in the levels of full-length caspase-3 or β-actin among the above treatments. Quantification of the Western blots, based on the ratio of caspase-3 fragments to full length caspase-3, showed that the treatment with 2 % isoflurane plus saline for 6 h (black bar) induced caspase-3 activation compared to the control condition treatment plus saline (white bar) (Fig. 1b) . A two-way ANOVA illustrated a significant interaction between the group (control condition versus isoflurane) and the treatment (saline versus VitC) on caspase-3 activation (F=4.712, P=0.042). A post hoc Bonferroni test showed that there was greater caspase-3 activation in the H4-APP cells following the treatment with isoflurane (black bar) as compared to the control condition (white bar) (P=0.020, Fig. 1b) , and there was less caspase-3 activation in the H4-APP cells following treatment with isoflurane plus VitC (net bar) compared to treatment with isoflurane plus saline (black bar) (P=0.023, Fig. 1b ).
VitC Attenuates Isoflurane-Induced Increases in ROS Levels
Isoflurane has been shown to increase ROS levels, which leads to caspase-3 activation [27, 28] . We therefore determined the effects of VitC on isoflurane-induced increases in ROS levels in the H4-APP cells. The quantitative ROS assay showed that there was a significant interaction between group (control condition versus isoflurane) and treatment (saline versus VitC) on ROS levels ( Fig. 2) : F=62.100, P<0.001. A post hoc Bonferroni test showed that there were greater ROS levels in the H4-APP cells following the treatment with isoflurane (black bar) as compared to the control condition (white bar) (P<0.001, Fig. 2 ) and that there were lower ROS levels in the H4-APP cells following the treatment with isoflurane plus VitC (net bar) as compared to the treatment with isoflurane plus saline (black bar) (P<0.001, Fig. 2) . VitC decreased the baseline amounts of ROS levels in the control condition. These data suggest that VitC could mitigate isoflurane-induced ROS accumulation.
VitC Attenuates Isoflurane-Induced Opening of mPTP
Given that VitC was able to mitigate isoflurane-induced ROS accumulation and caspase-3 activation, we then set out to determine whether VitC could also attenuate isofluraneinduced mitochondrial dysfunction. We specifically assessed the interaction of isoflurane and VitC on the opening of mPTP and levels of MMP and ATP in the B104 and H4-APP cells, respectively.
Treatment with 2 % isoflurane for 3 h induced the opening of mPTP in B104 cells as evidenced by the peak following the isoflurane treatment (peak 2) located There is lesser caspase-3 activation following the treatment with 2 % isoflurane plus 400 μM VitC for 6 h (lane 4) than that following the treatment with 2 % isoflurane plus saline for 6 h (lane 2). There is no significant difference in the levels of full-length caspase-3 and β-actin among the above treatments. b The quantification of the Western blots shows that the treatment with 2 % isoflurane plus saline for 6 h (black bar), but not the control condition plus 400 μM VitC for 6 h (gray bar), induces caspase-3 activation as compared to the control condition plus saline for 6 h (white bar) in H4-APP cells. The treatment with 400 μM VitC (net bar) attenuates the isoflurane-induced caspase-3 activation (black bar). N=6 in each group. Fig. 2 VitC attenuates the isoflurane-induced increases in ROS levels in H4-APP cells. A fluorescence staining of ROS shows that the treatment with 2 % isoflurane plus saline for 6 h (black bar) increases ROS levels as compared to the control condition plus saline for 6 h (white bar). There are lesser ROS levels following the treatment with isoflurane plus VitC (net bar) as compared to those following the treatment with isoflurane plus saline (black bar). N=6 in each group. ROS reactive oxygen species, APP amyloid precursor protein, VitC vitamin C to the left, as compared to the peak following the control condition (peak 3) (Fig. 3) . The peak following treatment with isoflurane plus VitC (peak 4) is located to the right of the peak following treatment with isoflurane plus saline (peak 2). Peak 1 was the positive control peak of mPTP opening; peak 5 was the peak following treatment with calcein, the negative control of mPTP opening. These data suggest that the isoflurane opened the mPTP and that VitC was able to mitigate this isoflurane-induced opening of mPTP.
VitC Attenuates Isoflurane-Induced Reduction in MMP Next, we assessed whether or not VitC could inhibit the isoflurane-induced decreases in the levels of MMP in the H4-APP cells. Immunocytochemistry staining of TMRE, the indicator of MMP, showed that the isoflurane treatment (b) decreased levels of MMP, detected by confocal microscopy, as compared to the control condition (a) in the H4-APP cells (Fig. 4a) . Moreover, VitC inhibited the isoflurane-induced reduction in MMP, as evidenced by greater TMRE staining in the cells treated with isoflurane plus VitC (d) compared to the cells treated with isoflurane plus saline (b) (Fig. 4a) .
JC-1 fluorescence ratio detection showed that the treatment with 2 % isoflurane plus saline (black bar) for 3 h decreased the levels of MMP as compared to the treatment with the control condition plus saline (white bar) (Fig. 4b) . A twoway ANOVA showed that there was a significant interaction between the group (control condition versus isoflurane) and the treatment (saline versus VitC) (F =4.847, P =0.040, Fig. 4b) . A post hoc Bonferroni test showed that there was a smaller MMP level in the H4-APP cells following treatment with isoflurane (black bar) compared to the control condition (white bar) (P<0.001, Fig. 4b) , and there was a higher MMP level in the H4-APP cells following treatment with isoflurane plus VitC (net bar) compared to treatment with isoflurane plus saline (black bar) (P=0.017, Fig. 4b ).
VitC Attenuates Isoflurane-Induced Reduction in ATP Levels
Finally, we assessed the possible interaction of isoflurane and VitC on ATP levels in the H4-APP cells. A two-way Fig. 5 ). Collectively, these results suggest that VitC was able to mitigate isoflurane-induced mitochondrial dysfunction, including both mPTP opening and the reduction in the levels of MMP and ATP, in the H4-APP cells.
VitC Ameliorates Isoflurane-Induced Cognitive Impairment
After discovering that VitC could mitigate isoflurane-induced cellular neurotoxicity, which can lead to cognitive impairment [27] , we consequently asked whether VitC would also be able to ameliorate the isoflurane-induced cognitive impairment seen in mice. Anesthesia, with 1.4 % isoflurane for 3 h, induced cognitive impairment in mice, as evidenced by the isoflurane-anesthesia-induced decreased freezing time of mice in the context test of FCS at 7 days (F=8.032, P=0.008, twoway ANOVA; P=0.034, post hoc Bonferroni test, Fig. 6a ) and in the tone test of FCS at 2 days (F=10.050, P=0.003, twoway ANOVA; P=0.041, post hoc Bonferroni test, Fig. 6b) . A post hoc Bonferroni test showed that there were greater freezing times for the mice treated with isoflurane plus VitC than those for the mice treated with isoflurane plus saline in the context test of FCS at 7 days (P=0.015, Fig. 6a ) and in the tone test of FCS at 2 days (P=0.004, Fig. 6b ). These findings suggest that VitC has the ability to ameliorate isofluraneinduced cognitive impairment in mice. Fig. 5 VitC attenuates the isoflurane-induced reduction in ATP levels in H4-APP cells. The treatment with 2 % isoflurane plus saline for 3 h (black bar) decreases ATP levels as compared to the control condition plus saline for 3 h (white bar). The treatment with 400 μM VitC for 3 h (gray bar) does not significantly alter the ATP levels as compared to the control condition plus saline for 3 h (white bar). Finally, the treatment with 2 % isoflurane plus 400 μM VitC for 3 h (net bar) leads to lesser reduction in ATP levels as compared to the treatment of 2 % isoflurane plus saline for 3 h (black bar). N=6 in each group. ATP adenosine triphosphate, VitC vitamin C Discussion ROS accumulation, mitochondrial dysfunction, and reduction in ATP levels have all been proposed as up-stream mechanisms of isoflurane-induced caspase-3 activation, while cognitive impairment has been suggested as the down-stream consequence of this isoflurane-induced caspase-3 activation [27, 28] . VitC may protect against the negative effects of oxidative stress and apoptosis [29] [30] [31] [32] [33] [34] [35] [36] . Therefore, in the present study, we assessed the interaction between isoflurane and VitC on caspase-3 activation, ROS accumulation, mitochondrial function, and ATP levels, in order to further illustrate the up-stream mechanisms and the down-stream consequences of isoflurane-induced caspase-3 activation. Moreover, we wished to explore the potential for targeted interventions into this isoflurane-induced neurotoxicity phenomenon and its associated neurobehavioral deficits.
We found that the VitC treatment attenuated the isofluraneinduced caspase-3 activation in the H4-APP cells (Fig. 1) . These data suggest that VitC could attenuate the cellular neurotoxicity of the anesthetic, isoflurane, and therefore may serve as a targeted intervention of this anesthesia's neurotoxicity. Future studies are needed to further investigate the application of VitC in treating and preventing anesthesia neurotoxicity. The outcomes of these studies would lead to safer anesthesia care for patients and better postoperative outcomes, particularly in AD patients and senior adults. Moreover, the results suggested that VitC could be used as a tool to investigate the up-stream mechanisms and the down-stream consequences of isoflurane-induced caspase-3 activation. For example, we may use VitC to further assess whether oxidative stress and mitochondrial dysfunction are parts of the upstream mechanisms and whether inflammation, DNA damages, and synaptic dysfunction are parts of the down-stream consequences.
Isoflurane-induced ROS elevation, mitochondrial dysfunction, and ATP reduction have been shown, at least partially, to be the up-stream mechanisms of the isoflurane-induced caspase-3 activation [27, 28] . We found that VitC attenuated the isoflurane-induced accumulation in ROS levels in the H4-APP cells (Fig. 2) , inhibited the isoflurane-induced opening of mPTP in B104 cells (Fig. 3) , mitigated the isofluraneinduced reduction in MMP in H4-APP cells (Fig. 4) , and attenuated the isoflurane-induced reduction in ATP levels in H4-APP cells (Fig. 5) . These data suggest that VitC could mitigate the isoflurane-induced caspase-3 activation by inhibiting the isoflurane-induced oxidative stress, mitochondrial dysfunction, and ATP reduction. In addition, these data further suggested that ROS accumulation, mitochondrial dysfunction (e.g., opening of mPTP and reduction in MMP), and ATP reduction could be the up-stream mechanisms of the isoflurane-induced caspase-3 activation.
Finally, we were able to demonstrate that VitC ameliorated the isoflurane-induced cognitive impairment observed in mice. These findings suggested that VitC could be used to ameliorate the neurobehavioral deficits induced by anesthesia, pending further studies. Moreover, these findings further demonstrate that isoflurane-induced cognitive impairment could be one of the consequences of the isoflurane-induced caspase-3 activation.
VitC has been shown to attenuate UV-induced apoptosis in human epidermoid carcinoma A431 cells [33] . Consistent 6 VitC attenuates the isoflurane-induced learning and memory impairment in mice. a The treatment with isoflurane plus saline (black bar) decreases the freezing time in the context test of the fear conditioning system (FCS) as compared to the control condition plus saline (white bar) at 7 days after isoflurane anesthesia in mice. VitC treatment alone (gray bar) does not significantly affect freezing time as compared to the control condition plus saline (white bar) in the context test of the FCS at 7 days after the isoflurane anesthesia. The treatment with isoflurane plus VitC (net bar) attenuates the isoflurane-induced reduction in freezing time in the context test of the FCS at 7 days after the treatment. b The treatment with isoflurane plus saline (black bar) decreases freezing time in the tone test of the FCS as compared to the control condition plus saline (white bar) at 2 days after the isoflurane anesthesia in mice. The VitC treatment alone (gray bar) does not significantly affect freezing time as compared to the control condition plus saline (white bar) in the tone test of the FCS at 48 h after the isoflurane anesthesia. However, VitC (net bar) attenuates the isoflurane-induced reduction in freezing time in the tone test of the FCS at 2 days after the treatment. N=10 in each group. FCS fear conditioning system, VitC vitamin C with that previous finding, we were able to show that VitC attenuated the isoflurane-induced caspase-3 activation in H4-APP cells. The studies by Lin et al. showed that VitC inhibited the UV-induced apoptosis via regulating Tet activity, DNA demethylation, and tumor suppressor gene activation. The data from our current studies suggested that VitC might attenuate the isoflurane-induced caspase-3 activation by inhibiting the isoflurane-induced ROS accumulation, mitochondrial dysfunction, and reduction in ATP levels. Moreover, we found that VitC was able to ameliorate the isoflurane-induced cognitive impairment in mice. Future studies should investigate other cellular and molecular mechanisms by which VitC might attenuate the isoflurane-induced neurotoxicity and neurobehavioral deficits. Results from these studies would lead to further investigations into the underlying mechanisms behind anesthesia's neurotoxicity and potential targeted interventions.
There are several limitations in the current studies. First, we did not assess the effects of different concentrations of VitC on the isoflurane-induced caspase-3 activation. It is possible that different concentrations of VitC may have different effects on the isoflurane-induced caspase-3 activation, increases in ROS levels, mitochondrial dysfunction, and reductions in ATP levels. Second, we did not determine whether VitC could attenuate the isoflurane-induced cognitive impairment through other behavioral methods, e.g., Morris water maze. Finally, we did not determine whether other antioxidant agents might also be able to attenuate isoflurane-induced neurotoxicity and neurobehavioral deficits. Nevertheless, the primary objective of the current study was to establish a system and to generate a concept. We will use this established system to systematically investigate the interaction of VitC (as well as other antioxidant agents, e.g., vitamin E) and isoflurane (as well as other anesthetics, e.g., sevoflurane) on neurotoxicity and neurobehavioral deficits in the future.
In conclusion, we found that VitC attenuated the isoflurane-induced caspase-3 activation, increases in ROS levels, opening of mPTP and decreases in MMP, and reduction in ATP levels in the cells. Moreover, VitC was able to ameliorate the isoflurane-induced cognitive impairment in mice. Pending further studies, these results suggested that VitC might mitigate the isoflurane-induced caspase-3 activation via ROS-, mitochondria-, and ATP-associated mechanisms, which may lead to the inhibition of isofluraneinduced cognitive impairment. Ultimately, our hope is that the findings from these studies will promote more research into the underlying mechanisms behind anesthesia's neurotoxicity, as well as targeted interventions of anesthesia neurotoxicity.
